CGTX — Cognition Therapeutics, Inc.

Summary of Cognition Therapeutics (CGTX) Q4 2024 Earnings Call

1. Key Financial Results and Metrics

• Net Loss: $34 million for the year ended December 31, 2024, compared to a net loss of $25.8 million in 2023.
• Loss Per Share: Remained stable at $0.86 per basic and diluted share for both years.
• Cash Position: Approximately $25 million in cash and cash equivalents as of December 31, 2024, with total obligated grant funds remaining from the NIA at $50 million.
• R&D Expenses: Increased to $41.7 million in 2024 from $37.2 million in 2023, primarily due to costs associated with ongoing Phase II trials.
• G&A Expenses: Decreased to $12.3 million from $13.5 million, attributed to lower equity-based compensation and professional fees.
• Capital Runway: Cash runway extended into Q4 2025 following the strategic decision to conclude the Phase II dry AMD study.

2. Strategic Updates and Business Highlights

• Focus on Zervimesine: The company is prioritizing the development of zervimesine (CT1812) for Alzheimer's disease and dementia with Lewy bodies (DLB), having shown strong efficacy signals in Phase II trials.
• Regulatory Strategy: Plans to submit final study documents to the FDA for end of Phase II meetings for both Alzheimer's and DLB, with discussions ongoing to ensure preparedness.
• Manufacturing Advances: Development of a novel chemical process for zervimesine's manufacture, with provisional patents filed and collaboration with a domestic CMO for commercial production.
• Business Development: Actively seeking partnerships for funding and development, with a focus on non-dilutive funding options.

3. Forward Guidance and Outlook

• Regulatory Meetings: Anticipated end of Phase II meetings with the FDA, expected to clarify clinical program pathways.
• Funding Strategy: The company is exploring various financing options to support clinical development, with confidence in securing necessary capital.
• Compliance with NASDAQ: Granted a six-month grace period to regain compliance with the minimum bid requirement, aiming to achieve this by September 2025.

4. Bad News, Challenges, or Points of Concern

• Net Loss: Continued significant net losses raise concerns about financial sustainability.
• Regulatory Risks: Uncertainty surrounding FDA meetings and the potential for approval pathways, particularly for DLB, where guidance is less defined compared to Alzheimer's.
• Funding Risks: The company acknowledges challenges in securing additional grant funding from the NIH, especially amid reported cutbacks.
• Market Competition: The competitive landscape for Alzheimer's and DLB treatments remains intense, with the need for clear differentiation and efficacy to attract partnerships and investment.

5. Notable Q&A Insights

• Biomarker Strategy: Plans to enrich participants in future studies based on tau levels, with no specific cutoff announced yet.
• Feedback on SHIMMER Data: Positive feedback from key opinion leaders (KOLs) and payers regarding zervimesine's potential, with ongoing efforts to publish findings.
• Dosing Considerations: The company is exploring dosing strategies for pivotal studies, likely below 300 mg, to optimize efficacy and minimize side effects.
• Partnership Interests: Multiple discussions ongoing with potential partners, but no specific deals confirmed yet.
• Regulatory Pathway: Emphasis on traditional Phase III study designs for Alzheimer's, with no indication that European approvals would be easier than in the U.S.

This summary encapsulates the key points from the earnings call, highlighting both the progress and challenges faced by Cognition Therapeutics as they advance their clinical programs.